Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2 clinical development.

Biotechnology

Aristea Therapeutics

James Mackay

Sara McCutchan

Deanne Reid

Nihar Bhakta

The Leadership Team at Aristea Therapeutics is responsible for guiding the strategic vision and direction of the company. This team, composed of key executives such as the President & CEO and Chief Medical Officers, oversees drug development initiatives, fosters partnerships, and ensures alignment with the company's goals to bring innovative therapies for inflammatory diseases to market, including the advancement of RIST4721 through Phase 2 clinical trials.

Leadership Team

About

Team members

Other teams at Aristea Therapeutics

Directors